Stockscreener 앱 받기
2.10
1.87%
-0.04
Grace Therapeutics Inc 주식(GRCE)의 최신 뉴스
GRCE Stock On Retail Watchlist: High-Stakes FDA Decision On Brain Bleed Drug Nears - Stocktwits
Grace (GRCE) Earnings Update: The Bottom-Line Figure Outpaces Its Comparison at the Close; Trading Response: Shares Finish 1.88% Higher in the Latest ReadingTech Earnings Analysis - vinanet.vn
Opaleye Management buys $24,206 of Grace Therapeutics stock - Investing.com
Grace Therapeutics (GRCE) holder lifts indirect stake to 2.76M shares - Stock Titan
Major Investor Quietly Boosts Stake in Grace Therapeutics With Fresh Buy-In - TipRanks
Craig-Hallum Maintains Grace Therapeutics(GRCE.US) With Buy Rating, Announces Target Price $4 - Moomoo
GRCE Stock On Track For Worst Week In 5.5 Years — What’s Driving The Selloff? - Stocktwits
Grace Therapeutics (GRCE): ADAR1 group discloses 9.9% beneficial stake via warrants - Stock Titan
Grace Therapeutics (GRCE) investor group reports 6.75% stake via convertibles - Stock Titan
Grace Therapeutics, Inc. Reports Impairment charges for the First Quarter Ended June 30, 2026 - marketscreener.com
Grace Therapeutics, Inc. (NASDAQ: GRCE) Share Price, GRCE Stock News, GRCE Share Price & Updates - Kalkine
GRCE Q2 2026 Earnings: Narrower-than-Expected Loss Delivers 74.42% EPS SurpriseManagement Guidance Update - vinanet.vn
Grace Therapeutics Q1 Results: EPS Misses Estimate, Losses Widen - scanx.trade
Form 8K Grace Therapeutics, Inc For: 13 August By Investing.com - Investing.com Nigeria
Grace Therapeutics Announces First Quarter 2027 Financial Results, Provides Business Update - The Manila Times
Grace Therapeutics Reports $15.8 Million First-Quarter Net Loss - Quiver Quantitative
Grace Therapeutics, Inc. Q1 2027: Net loss $(15.8)M, EPS $(0.91) — 10-Q Summary - TradingView
Grace Therapeutics (GRCE) books $13.5M R&D impairment, extends cash runway to 2028 - Stock Titan
Grace Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2026 - marketscreener.com
Grace Therapeutics posts investor deck on IV nimodipine candidate GTx-104 for aneurysmal subarachnoid hemorrhage - Bitget
Grace Therapeutics (GRCE) completes $9.99M Rule 506(b) private equity raise - Stock Titan
GRCE Q2 2026 Earnings: Narrower-Than-Expected Loss Delivers a 74.42% Surprise Despite No RevenueGuidance vs Actual - vinanet.vn
Grace Therapeutics (GRCE): Opaleye reports 2.75M-share, 13.07% ownership stake - Stock Titan
Grace Therapeutics, Inc. Revenue Breakdown – NASDAQ:GRCE - TradingView
GRCE Q2 2026 Earnings: 74.42% EPS Surprise as Loss Narrows to -$0.06SaaS Earnings Trends - vinanet.vn
Grace Therapeutics Raises Capital to Advance GTx-104 Program - TipRanks
Grace Therapeutics Raises $10 Million in Private Placement, Grants Registration Rights - TradingView
Grace Therapeutics announces securities purchase agreement for $10M private placement - ROI-NJ
Grace Therapeutics (GRCE) Raises $10M in Private Placement Amid High Price-to-Sales Valuation - GuruFocus
GRCE Q1'26 Earnings: EPS estimate is (0.13) USD - TradingView
Grace Therapeutics Secures $10M Private Placement Agreement - Intellectia AI
Grace Therapeutics Expects Funding to Extend Cash Runway Through 2028 - Stock Titan
Grace Therapeutics raises $10 million in private placement By Investing.com - Investing.com Australia
Grace Therapeutics raises $10 million in private placement - Investing.com
Grace Therapeutics raises $10M in private place... - Pluang
Grace Therapeutics Announces $10 Million Private Placement Financing to Support GTx-104 Development - Quiver Quantitative
Grace Therapeutics Announces $10 Million Private Placement - Moomoo
Grace Therapeutics prices USD 10 million private placement at USD 2.1 per share - Bitget
Grace Therapeutics, Inc. announced that it expects to receive $9.999998 million in funding - marketscreener.com
GRCE Q2 2026 Earnings: 74.4% EPS Surprise Signals Stronger Cost DisciplineEarnings Per Share - vinanet.vn
GRCE Q1'26 Earnings: revenue estimate is 0 USD - TradingView
Grace Therapeutics Receives Type a Meeting Minutes from FDA and Provides Update on GTx-104 Clinical-Stage Injectable Formulation - marketscreener.com
Grace Therapeutics (GRCE) FDA Meeting Highlights Manufacturing Compliance Focus, Market Implies High Growth - GuruFocus
Grace Therapeutics receives FDA meeting minutes on GTx-104 - Investing.com
Grace Therapeutics advances dual-source manufacturing for GTx-104 - TipRanks
Grace receives FDA Type A meeting minutes; advances dual-source manufacturing toward NDA resubmission - TradingView
Grace Therapeutics Announces Receipt of Type A Meeting Minutes from U.S. Food and Drug Administration - The Manila Times
Grace Therapeutics receives FDA meeting minutes on GTx-104 By Investing.com - Investing.com Canada
Grace Therapeutics Says FDA Minutes Confirm No Clinical Safety or Efficacy Deficiencies in GTx-104 Review, Advances Dual-Source Manufacturing Plan Toward NDA Resubmission - Quiver Quantitative
Grace Therapeutics Advances Second U.S. Manufacturing Route for GTx-104 - Stock Titan
Grace Therapeutics, Inc (GRCE) Institutional Confidence - TradingKey
Grace Therapeutics, Inc (GRCE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Grace Therapeutics, Inc (GRCE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Grace Therapeutics, Inc (GRCE) Cash Flow - TradingKey
Price to sales forward of Grace Therapeutics, Inc. – FWB:L8S - TradingView
GRCE Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Per Share - vinanet.vn
GRCE|Grace Therapeutics, Inc|Price:2.330|Chg%:-0.020 - TradingKey
Price to earnings forward of Grace Therapeutics, Inc. – FWB:L8S - TradingView
0.86%
0.31%
자본화:
|
볼륨(24시간):